{"id": "article-17389_0", "title": "Alpers-Huttenlocher Syndrome -- Continuing Education Activity", "content": "Alpers-Huttenlocher syndrome (AHS) is a rare disease that is important to consider in children presenting with neurologic and hepatic symptoms. This activity provides the essential information needed to recognize the symptoms of AHS, properly evaluate patients, provide treatment, and limit complications. This activity highlights the role of the interprofessional team in evaluating and treating patients with this condition.", "contents": "Alpers-Huttenlocher Syndrome -- Continuing Education Activity. Alpers-Huttenlocher syndrome (AHS) is a rare disease that is important to consider in children presenting with neurologic and hepatic symptoms. This activity provides the essential information needed to recognize the symptoms of AHS, properly evaluate patients, provide treatment, and limit complications. This activity highlights the role of the interprofessional team in evaluating and treating patients with this condition."}
{"id": "article-17389_1", "title": "Alpers-Huttenlocher Syndrome -- Continuing Education Activity", "content": "Objectives: Describe how to properly evaluate a patient for Alpers-Huttenlocher syndrome. Outline the treatment and management options available for patients with Alpers-Huttenlocher syndrome. Summarize the medications that should be avoided in patients with Alpers-Huttenlocher syndrome. Explain interprofessional team strategies to improve care coordination and communication to advance care for patients with Alpers-Huttenlocher syndrome and improve patient outcomes. Access free multiple choice questions on this topic.", "contents": "Alpers-Huttenlocher Syndrome -- Continuing Education Activity. Objectives: Describe how to properly evaluate a patient for Alpers-Huttenlocher syndrome. Outline the treatment and management options available for patients with Alpers-Huttenlocher syndrome. Summarize the medications that should be avoided in patients with Alpers-Huttenlocher syndrome. Explain interprofessional team strategies to improve care coordination and communication to advance care for patients with Alpers-Huttenlocher syndrome and improve patient outcomes. Access free multiple choice questions on this topic."}
{"id": "article-17389_2", "title": "Alpers-Huttenlocher Syndrome -- Introduction", "content": "Alpers-Huttenlocher syndrome (AHS) is an autosomal recessive disease caused by a\u00a0mutation in the\u00a0POLG1 gene, which leads to the reduced functionality of polymerase gamma - a key component of mitochondrial DNA (mtDNA) replication and repair.\u00a0\u00a0The brain and liver\u00a0are the classic organs\u00a0affected by this disease due to their\u00a0high energy\u00a0demand and the proportional need for\u00a0mitochondria.\u00a0Decreased mitochondria in these organ systems lead to various symptoms, with seizures and liver failure being the most common.\u00a0 This pathology is a rapidly progressive disease that presents early in life and invariably ends in a fatality. [1]", "contents": "Alpers-Huttenlocher Syndrome -- Introduction. Alpers-Huttenlocher syndrome (AHS) is an autosomal recessive disease caused by a\u00a0mutation in the\u00a0POLG1 gene, which leads to the reduced functionality of polymerase gamma - a key component of mitochondrial DNA (mtDNA) replication and repair.\u00a0\u00a0The brain and liver\u00a0are the classic organs\u00a0affected by this disease due to their\u00a0high energy\u00a0demand and the proportional need for\u00a0mitochondria.\u00a0Decreased mitochondria in these organ systems lead to various symptoms, with seizures and liver failure being the most common.\u00a0 This pathology is a rapidly progressive disease that presents early in life and invariably ends in a fatality. [1]"}
{"id": "article-17389_3", "title": "Alpers-Huttenlocher Syndrome -- Etiology", "content": "Alpers-Huttenlocher syndrome is a mitochondrial disorder caused by an autosomal recessive\u00a0mutation in the\u00a0POLG1 gene resulting in damage to polymerase gamma. [2] The inheritance of a heterozygous mutation in POLG1 leads to the classic presentation of the disease between 2 and 4 years of age.\u00a0 However, the presence of a homozygous mutation\u00a0in POLG1 is associated with a later and\u00a0milder\u00a0presentation, between 17 to 24 years of age. [3]", "contents": "Alpers-Huttenlocher Syndrome -- Etiology. Alpers-Huttenlocher syndrome is a mitochondrial disorder caused by an autosomal recessive\u00a0mutation in the\u00a0POLG1 gene resulting in damage to polymerase gamma. [2] The inheritance of a heterozygous mutation in POLG1 leads to the classic presentation of the disease between 2 and 4 years of age.\u00a0 However, the presence of a homozygous mutation\u00a0in POLG1 is associated with a later and\u00a0milder\u00a0presentation, between 17 to 24 years of age. [3]"}
{"id": "article-17389_4", "title": "Alpers-Huttenlocher Syndrome -- Epidemiology", "content": "Approximately 1 in 100000 children will develop Alpers-Huttenlocher syndrome, with males and females being affected equally. There appears to be a slightly higher carrier frequency in people of Northern European descent, although there are reports of the condition in many ethnic groups. [3]", "contents": "Alpers-Huttenlocher Syndrome -- Epidemiology. Approximately 1 in 100000 children will develop Alpers-Huttenlocher syndrome, with males and females being affected equally. There appears to be a slightly higher carrier frequency in people of Northern European descent, although there are reports of the condition in many ethnic groups. [3]"}
{"id": "article-17389_5", "title": "Alpers-Huttenlocher Syndrome -- Pathophysiology", "content": "An autosomal recessive mutation in POLG1 leads to decreased polymerase gamma functionality,\u00a0leading to a reduction\u00a0of mitochondrial DNA. [4] Mitochondria are present in high numbers in tissue with high energy requirements - such as the central nervous system, liver, and skeletal muscle. This reduction in mitochondrial support leads to the symptoms of AHS. [3]", "contents": "Alpers-Huttenlocher Syndrome -- Pathophysiology. An autosomal recessive mutation in POLG1 leads to decreased polymerase gamma functionality,\u00a0leading to a reduction\u00a0of mitochondrial DNA. [4] Mitochondria are present in high numbers in tissue with high energy requirements - such as the central nervous system, liver, and skeletal muscle. This reduction in mitochondrial support leads to the symptoms of AHS. [3]"}
{"id": "article-17389_6", "title": "Alpers-Huttenlocher Syndrome -- Histopathology", "content": "The primary organs in Alpers-Huttenlocher syndrome demonstrating histologic changes are the liver and brain. Neural tissue from the cerebral cortex shows spongiosis, neuronal loss, and astrocytosis. These findings correlate with the progressive cognitive decline seen with the progression of the disease. The hepatic findings are more specific to AHS. A minimum of three of the following eight criteria must be present, in the absence of Wilson disease: bridging fibrosis or cirrhosis, bile ductular proliferation, the collapse of liver plate cells, hepatocyte dropout or focal necrosis with or without portal inflammation, microvesicular steatosis, oncocytic change, regenerative nodules, and parenchymal disease or disorganization of the normal lobular architecture. [5]", "contents": "Alpers-Huttenlocher Syndrome -- Histopathology. The primary organs in Alpers-Huttenlocher syndrome demonstrating histologic changes are the liver and brain. Neural tissue from the cerebral cortex shows spongiosis, neuronal loss, and astrocytosis. These findings correlate with the progressive cognitive decline seen with the progression of the disease. The hepatic findings are more specific to AHS. A minimum of three of the following eight criteria must be present, in the absence of Wilson disease: bridging fibrosis or cirrhosis, bile ductular proliferation, the collapse of liver plate cells, hepatocyte dropout or focal necrosis with or without portal inflammation, microvesicular steatosis, oncocytic change, regenerative nodules, and parenchymal disease or disorganization of the normal lobular architecture. [5]"}
{"id": "article-17389_7", "title": "Alpers-Huttenlocher Syndrome -- History and Physical", "content": "The first step to diagnosing Alpers-Huttenlocher syndrome is recognizing the triad of refractory seizures, psychomotor regression, and hepatopathy. Patients may experience blindness - first temporarily, but often permanently.\u00a0 Other symptoms include migraines with possible hallucinations, ataxia, spastic paraparesis, cognitive impairment, anxiety, and depression. [6] A confirmation of the diagnosis is possible with polymerase gamma gene sequencing, liver biopsy,\u00a0and ultimately\u00a0autopsy.", "contents": "Alpers-Huttenlocher Syndrome -- History and Physical. The first step to diagnosing Alpers-Huttenlocher syndrome is recognizing the triad of refractory seizures, psychomotor regression, and hepatopathy. Patients may experience blindness - first temporarily, but often permanently.\u00a0 Other symptoms include migraines with possible hallucinations, ataxia, spastic paraparesis, cognitive impairment, anxiety, and depression. [6] A confirmation of the diagnosis is possible with polymerase gamma gene sequencing, liver biopsy,\u00a0and ultimately\u00a0autopsy."}
{"id": "article-17389_8", "title": "Alpers-Huttenlocher Syndrome -- Evaluation", "content": "Seizure activity is often an early feature of the disease and should undergo an evaluation with an\u00a0electroencephalography (EEG). EEG findings in the early stages of the disease have shown a focal slowing of the frequency with epileptiform discharges from the occipital region. [3] One report showed that a characteristic EEG finding is unilateral occipital rhythmic high-amplitude delta with superimposed (poly)spikes (RHADS). [7] Brain magnetic resonance imaging (MRI) may aid in supporting an\u00a0overall diagnosis of Alpers-Huttenlocher syndrome by showing gray matter involvement in the posterior cortical structures and thalamus,\u00a0in addition to the involvement of the occipital cortex - the portion of the brain with the highest metabolic activity. [8]", "contents": "Alpers-Huttenlocher Syndrome -- Evaluation. Seizure activity is often an early feature of the disease and should undergo an evaluation with an\u00a0electroencephalography (EEG). EEG findings in the early stages of the disease have shown a focal slowing of the frequency with epileptiform discharges from the occipital region. [3] One report showed that a characteristic EEG finding is unilateral occipital rhythmic high-amplitude delta with superimposed (poly)spikes (RHADS). [7] Brain magnetic resonance imaging (MRI) may aid in supporting an\u00a0overall diagnosis of Alpers-Huttenlocher syndrome by showing gray matter involvement in the posterior cortical structures and thalamus,\u00a0in addition to the involvement of the occipital cortex - the portion of the brain with the highest metabolic activity. [8]"}
{"id": "article-17389_9", "title": "Alpers-Huttenlocher Syndrome -- Treatment / Management", "content": "Treatment for Alpers-Huttenlocher syndrome is supportive and eventually palliative. Clinicians should weigh the benefits of seizure management against the risk of side effects.\u00a0 If prescribing anticonvulsants, the newer generation\u00a0(lamotrigine, topiramate, oxcarbazepine, primidone)\u00a0is the recommendation due to a lower hepatic processing burden. Valproic acid and sodium divalproate should be avoided to prevent accelerated\u00a0hepatic damage.\u00a0Impaired gluconeogenesis may lead to nutritional deficiencies.\u00a0 Small, frequent, low-protein meals are recommended. Eventually, as the patient's disease progresses, a gastrostomy feeding tube can be offered to supplement nutritional status. Long-term respiratory support is often needed, with the use of tracheostomy and mechanical ventilation. Pain medications and muscle relaxants should be available to keep the patient comfortable. [3]", "contents": "Alpers-Huttenlocher Syndrome -- Treatment / Management. Treatment for Alpers-Huttenlocher syndrome is supportive and eventually palliative. Clinicians should weigh the benefits of seizure management against the risk of side effects.\u00a0 If prescribing anticonvulsants, the newer generation\u00a0(lamotrigine, topiramate, oxcarbazepine, primidone)\u00a0is the recommendation due to a lower hepatic processing burden. Valproic acid and sodium divalproate should be avoided to prevent accelerated\u00a0hepatic damage.\u00a0Impaired gluconeogenesis may lead to nutritional deficiencies.\u00a0 Small, frequent, low-protein meals are recommended. Eventually, as the patient's disease progresses, a gastrostomy feeding tube can be offered to supplement nutritional status. Long-term respiratory support is often needed, with the use of tracheostomy and mechanical ventilation. Pain medications and muscle relaxants should be available to keep the patient comfortable. [3]"}
{"id": "article-17389_10", "title": "Alpers-Huttenlocher Syndrome -- Differential Diagnosis", "content": "Alpers-Huttenlocher syndrome requires differentiation from the other mitochondrial disorders associated with POLG gene mutations. These include: Childhood myocerbro-hepatopathy This disease has some overlapping features with AHS, so it is important to recognize the unique features. Childhood myocerebro-hepatopathy syndrome\u00a0leads to liver failure and encephalopathy. Helpful distinguishing\u00a0symptoms for this entity\u00a0include lactic acidosis, hearing loss, cyclic vomiting, and lack of prominent seizure activity. This disease usually presents by six months of age - earlier than the typical onset of AHS, which is between 2 to 4 years old. [9] Ataxia-neuropathy syndrome Myoclonus epilepsy myopathy sensory ataxia Autosomal recessive progressive external ophthalmoplegia plus Autosomal dominant progressive ophthalmoplegia plus. [10]", "contents": "Alpers-Huttenlocher Syndrome -- Differential Diagnosis. Alpers-Huttenlocher syndrome requires differentiation from the other mitochondrial disorders associated with POLG gene mutations. These include: Childhood myocerbro-hepatopathy This disease has some overlapping features with AHS, so it is important to recognize the unique features. Childhood myocerebro-hepatopathy syndrome\u00a0leads to liver failure and encephalopathy. Helpful distinguishing\u00a0symptoms for this entity\u00a0include lactic acidosis, hearing loss, cyclic vomiting, and lack of prominent seizure activity. This disease usually presents by six months of age - earlier than the typical onset of AHS, which is between 2 to 4 years old. [9] Ataxia-neuropathy syndrome Myoclonus epilepsy myopathy sensory ataxia Autosomal recessive progressive external ophthalmoplegia plus Autosomal dominant progressive ophthalmoplegia plus. [10]"}
{"id": "article-17389_11", "title": "Alpers-Huttenlocher Syndrome -- Toxicity and Adverse Effect Management", "content": "Valproic acid is appropriate in the management of seizures - a common feature in Alpers-Huttenlocher syndrome.\u00a0However, valproic acid has been shown to cause a rapid progression of liver failure in patients with AHS.\u00a0For this reason, it is critical to diagnose AHS early to avoid\u00a0this medication and the detrimental effects it may have on the patient's clinical course. [3]", "contents": "Alpers-Huttenlocher Syndrome -- Toxicity and Adverse Effect Management. Valproic acid is appropriate in the management of seizures - a common feature in Alpers-Huttenlocher syndrome.\u00a0However, valproic acid has been shown to cause a rapid progression of liver failure in patients with AHS.\u00a0For this reason, it is critical to diagnose AHS early to avoid\u00a0this medication and the detrimental effects it may have on the patient's clinical course. [3]"}
{"id": "article-17389_12", "title": "Alpers-Huttenlocher Syndrome -- Prognosis", "content": "The prognosis for patients with Alpers-Huttenlocher syndrome is poor, with patients surviving less than 4 years after the initial presentation of symptoms. Common causes of death are fatal encephalopathy and liver failure. [1]", "contents": "Alpers-Huttenlocher Syndrome -- Prognosis. The prognosis for patients with Alpers-Huttenlocher syndrome is poor, with patients surviving less than 4 years after the initial presentation of symptoms. Common causes of death are fatal encephalopathy and liver failure. [1]"}
{"id": "article-17389_13", "title": "Alpers-Huttenlocher Syndrome -- Complications", "content": "Patients with Alpers-Huttenlocher syndrome can expect to experience numerous complications with the progression of the disease. Several features of end-stage AHS may find their explanation with the specific neural structures affected. Blindness is attributable to damage to the occipital cortex. Ataxia is traceable to the loss of Purkinje cells in the cerebellum. Loss of central respiratory drive often leads to hypoxia and possibly placement of a tracheostomy tube. Spastic paraparesis results from damage to the cerebral cortex.\u00a0 This spasticity may lead to difficulty walking, with the ultimate loss of the ability to walk. Decreased bulbar reflexes, in addition to muscle weakness, may cause\u00a0dysphagia-\u00a0leading patients to aspirate or become malnourished.\u00a0If the dysphagia\u00a0is severe, families may consider\u00a0the placement of a gastrostomy tube. [6]", "contents": "Alpers-Huttenlocher Syndrome -- Complications. Patients with Alpers-Huttenlocher syndrome can expect to experience numerous complications with the progression of the disease. Several features of end-stage AHS may find their explanation with the specific neural structures affected. Blindness is attributable to damage to the occipital cortex. Ataxia is traceable to the loss of Purkinje cells in the cerebellum. Loss of central respiratory drive often leads to hypoxia and possibly placement of a tracheostomy tube. Spastic paraparesis results from damage to the cerebral cortex.\u00a0 This spasticity may lead to difficulty walking, with the ultimate loss of the ability to walk. Decreased bulbar reflexes, in addition to muscle weakness, may cause\u00a0dysphagia-\u00a0leading patients to aspirate or become malnourished.\u00a0If the dysphagia\u00a0is severe, families may consider\u00a0the placement of a gastrostomy tube. [6]"}
{"id": "article-17389_14", "title": "Alpers-Huttenlocher Syndrome -- Deterrence and Patient Education", "content": "Due to the progressive nature of Alpers-Huttenlocher syndrome, patients and families will need frequent counsel throughout the course of the disease.\u00a0 Families should be educated about the general progression of the disease and be trained on specific skills as the needs arise.\u00a0 Due to the loss of mobility and cognitive abilities, the burden of care is likely to grow in the later stages of the disease.\u00a0 It is crucial to ensure the family has the resources they need at home to deliver the patient care and treatment required.\u00a0\u00a0Genetic counseling may also be of value if future pregnancies are a consideration.", "contents": "Alpers-Huttenlocher Syndrome -- Deterrence and Patient Education. Due to the progressive nature of Alpers-Huttenlocher syndrome, patients and families will need frequent counsel throughout the course of the disease.\u00a0 Families should be educated about the general progression of the disease and be trained on specific skills as the needs arise.\u00a0 Due to the loss of mobility and cognitive abilities, the burden of care is likely to grow in the later stages of the disease.\u00a0 It is crucial to ensure the family has the resources they need at home to deliver the patient care and treatment required.\u00a0\u00a0Genetic counseling may also be of value if future pregnancies are a consideration."}
{"id": "article-17389_15", "title": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Patients with Alpers-Huttenlocher syndrome require a collaborative effort from multiple specialties and supportive/specialty-trained nursing services, working collaboratively as an interprofessional team. There is no cure for Alpers-Huttenlocher syndrome at this time, so treatment should focus on symptom management. As discussed previously, the primary\u00a0systems involved in this disease are the\u00a0hepatic and central nervous systems. Seizures are often the presenting symptom and will need to be followed by neurology. With the progression of the disease,\u00a0motor skills, and muscle\u00a0strength\u00a0decline, necessitating the services of physical therapy and occupational therapy. Liver failure\u00a0may cause coagulopathies and hypoglycemia, leading to\u00a0the addition of gastrointestinal specialists, hematology, and nutritional support to the team. Due to the relentless nature of this disease, chaplain and psychiatric care should be offered for the patients. Ultimately, a palliative care team should discuss the treatment options and help the family and patients make the decisions they feel will result in the best quality of life. [6]", "contents": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes. Patients with Alpers-Huttenlocher syndrome require a collaborative effort from multiple specialties and supportive/specialty-trained nursing services, working collaboratively as an interprofessional team. There is no cure for Alpers-Huttenlocher syndrome at this time, so treatment should focus on symptom management. As discussed previously, the primary\u00a0systems involved in this disease are the\u00a0hepatic and central nervous systems. Seizures are often the presenting symptom and will need to be followed by neurology. With the progression of the disease,\u00a0motor skills, and muscle\u00a0strength\u00a0decline, necessitating the services of physical therapy and occupational therapy. Liver failure\u00a0may cause coagulopathies and hypoglycemia, leading to\u00a0the addition of gastrointestinal specialists, hematology, and nutritional support to the team. Due to the relentless nature of this disease, chaplain and psychiatric care should be offered for the patients. Ultimately, a palliative care team should discuss the treatment options and help the family and patients make the decisions they feel will result in the best quality of life. [6]"}
{"id": "article-17389_16", "title": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes", "content": "The nursing staff should assist with patient and family education, discussing the need to take seizure precautions. The nurses can also assist with the coordination of assistance with daily living activities. Often the nurse will identify the progression of the disease and need to report to the clinician the need for additional care. Home health nurses will often manage the care of the patient until a palliative care team assumes management. Nurses must work in conjunction with the clinicians to assure the patient's family is well educated about the clinical course, and coordination of care is achieved.", "contents": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes. The nursing staff should assist with patient and family education, discussing the need to take seizure precautions. The nurses can also assist with the coordination of assistance with daily living activities. Often the nurse will identify the progression of the disease and need to report to the clinician the need for additional care. Home health nurses will often manage the care of the patient until a palliative care team assumes management. Nurses must work in conjunction with the clinicians to assure the patient's family is well educated about the clinical course, and coordination of care is achieved."}
{"id": "article-17389_17", "title": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Valproic acid is appropriate in managing seizures, but it has been shown to cause a rapid progression of liver failure in patients with AHS.\u00a0For this reason, it is critical to avoid\u00a0this medication and the detrimental effects it may have on the patient's clinical course as long as possible. Once initiated, the pharmacist needs to assist the clinical team in monitoring for toxicity and advice the lowest dose possible. [3] An interprofessional approach to the management of clinicians, pharmacists, and nurses will produce the best outcomes in the care of Alpers-Huttenlocher syndrome. [Level 5]", "contents": "Alpers-Huttenlocher Syndrome -- Enhancing Healthcare Team Outcomes. Valproic acid is appropriate in managing seizures, but it has been shown to cause a rapid progression of liver failure in patients with AHS.\u00a0For this reason, it is critical to avoid\u00a0this medication and the detrimental effects it may have on the patient's clinical course as long as possible. Once initiated, the pharmacist needs to assist the clinical team in monitoring for toxicity and advice the lowest dose possible. [3] An interprofessional approach to the management of clinicians, pharmacists, and nurses will produce the best outcomes in the care of Alpers-Huttenlocher syndrome. [Level 5]"}
{"id": "article-17389_18", "title": "Alpers-Huttenlocher Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Alpers-Huttenlocher Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}